Abstract

The use of psychedelic substances at sub-sensorium ‘microdoses’, has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers (n = 4050) and non-microdosers (n = 4653) via a mobile application. Psilocybin was the most commonly used microdose substances in our sample (85%) and we identified diverse microdose practices with regard to dosage, frequency, and the practice of stacking which involves combining psilocybin with non-psychedelic substances such as Lion’s Mane mushrooms, chocolate, and niacin. Microdosers were generally similar to non-microdosing controls with regard to demographics, but were more likely to report a history of mental health concerns. Among individuals reporting mental health concerns, microdosers exhibited lower levels of depression, anxiety, and stress across gender. Health and wellness-related motives were the most prominent motives across microdosers in general, and were more prominent among females and among individuals who reported mental health concerns. Our results indicate health and wellness motives and perceived mental health benefits among microdosers, and highlight the need for further research into the mental health consequences of microdosing including studies with rigorous longitudinal designs.

Highlights

  • We aim to contribute to the literature on microdosing by further characterizing microdosers and microdosing practices, including a detailed assessment of combining psychedelic and non-psychedelic substances

  • The inclusion of a non-microdose comparison group that was similar with regard to important demographics, substance use, and mental health factors constitutes a distinct contribution of our findings to understanding mental health and microdosing

  • Controlled clinical trials are required to more confidently elucidate the potential risks and benefits of psychedelic microdosing, the present findings suggest that microdosing psychedelics does not appear to be associated with increased acute negative outcomes, even among potentially vulnerable groups such as those with mental health concerns

Read more

Summary

Objectives

We aim to contribute to the literature on microdosing by further characterizing microdosers and microdosing practices, including a detailed assessment of combining psychedelic and non-psychedelic substances

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.